Ryan B. Gaspar

Ryan B. Gaspar

Auto-generated profile, based on publicly available information

Ryan B. Gaspar

Department of Physiology and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
AGAndrew Gibb
Andrew Gibb
EMEmma K. Murray
Emma K. Murray
AHAnh T. Huynh
Anh T. Huynh
RGRyan B. Gaspar
Ryan B. Gaspar
TPTori L. Ploesch
Tori L. Ploesch
JEJohn W. Elrod
John W. Elrod

18 September 2024 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
Khanh DoanKhanh Doan
Khanh Doan
TLTimothy S. Luongo
Timothy S. Luongo
TTThato T. Ts’olo
Thato T. Ts’olo
WLWon Dong Lee
Won Dong Lee
DFDavid W. Frederick
David W. Frederick
JBJoseph A. Baur
Joseph A. Baur

20 November 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
SMSarmistha Mukherjee
Sarmistha Mukherjee
RARicardo A. Velázquez Aponte
Ricardo A. Velázquez Aponte
CPCaroline E. Perry
Caroline E. Perry
WLWon Dong Lee
Won Dong Lee
KJKevin A. Janssen
Kevin A. Janssen
JBJoseph A. Baur
Joseph A. Baur
Nicotinamide adenine dinucleotide (NAD + ) precursor supplementation shows metabolic and functional benefits in rodent models of disease and is being explored as potential therapeutic strategy in humans. However, the wide range of processes that involve NAD + in every cell and subcellular compartment make it difficult to narrow down the mechanisms of action. Here we show that the rate of liver regeneration is closely associated with the concentration of NAD + in hepatocyte mitochondria. We find that the mitochondrial NAD + concentration in hepatocytes of male mice is determined by the expression of the transporter SLC25A51 (MCART1). The heterozygous loss of SLC25A51 modestly decreases mitochondrial NAD + content in multiple tissues and impairs liver regeneration, whereas the hepatocyte-specific overexpression of SLC25A51 is sufficient to enhance liver regeneration comparably to the effect of systemic NAD + precursor supplements. This benefit is observed even though NAD + levels are increased only in mitochondria. Thus, the hepatocyte mitochondrial NAD + pool is a key determinant of the rate of liver regeneration.

25 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAndrew Gibb
Andrew Gibb
KLKyle LaPenna
Kyle LaPenna
RGRyan B. Gaspar
Ryan B. Gaspar
NLNadina R. Latchman
Nadina R. Latchman
YTYinfei Tan
Yinfei Tan
JEJohn W. Elrod
John W. Elrod
Background: Heart failure with preserved ejection fraction (HFpEF) accounts for ∼50% of HF cases, with no effective treatments. The ZSF1-obese rat model recapitulates numerous clinical features of HFpEF including hypertension, obesity, metabolic syndrome, exercise intolerance, and LV diastolic dysfunction. Here, we utilized a systems-biology approach to define the early metabolic and transcriptional signatures to gain mechanistic insight into the pathways contributing to HFpEF development. Methods: Male ZSF1-obese, ZSF1-lean hypertensive controls, and WKY (wild-type) controls were compared at 14w of age for extensive physiological phenotyping and LV tissue harvesting for unbiased metabolomics, RNA-sequencing, and assessment of mitochondrial morphology and function. Utilizing ZSF1-lean and WKY controls enabled a distinction between hypertension-driven molecular changes contributing to HFpEF pathology, versus hypertension + metabolic syndrome. Results: ZSF1-obese rats displayed numerous clinical features of HFpEF. Comparison of ZSF1-lean vs WKY (i.e., hypertension-exclusive effects) revealed metabolic remodeling suggestive of increased aerobic glycolysis, decreased β-oxidation, and dysregulated purine and pyrimidine metabolism with few transcriptional changes. ZSF1-obese rats displayed worsened metabolic remodeling and robust transcriptional remodeling highlighted by the upregulation of inflammatory genes and downregulation of the mitochondrial structure/function and cellular metabolic processes. Integrated network analysis of metabolomic and RNAseq datasets revealed downregulation of nearly all catabolic pathways contributing to energy production, manifesting in a marked decrease in the energetic state (i.e., reduced ATP/ADP, PCr/ATP). Cardiomyocyte ultrastructure analysis revealed decreased mitochondrial area, size, and cristae density, as well as increased lipid droplet content in HFpEF hearts. Mitochondrial function was also impaired as demonstrated by decreased substrate-mediated respiration and dysregulated calcium handling. Conclusions: Collectively, the integrated omics approach applied here provides a framework to uncover novel genes, metabolites, and pathways underlying HFpEF, with an emphasis on mitochondrial energy metabolism as a potential target for intervention.